United Health Products, Inc. · OTC:UEEC
United Health Products — Investor Presentation (October 2021)
12 slides from United Health Products's investor presentation, Oct 14, 2021
Slide 1: Investor Presentation October 2021
OCTOBER 2021 Products Investor Presentation
Slide 2: Disclaimer
DISCLAIMER This presentation and the accompanying commentary contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts for future events. Forward-looking statements may be identi
Slide 3: Agenda
AGENDA = Company Overview = HemoStyp® Overview = Class Ill U.S. Market Potential = Class Ill PMA Application Status = Other Market Opportunities = Post-PMA Decision Strategy United Health Products
Slide 4: Company Snapshot
COMPANY SNAPSHOT (OTC MKT: “UEEC”) Q Public market and capital structure statistics © 226.5 million shares outstanding - $210,000,000 market capitalization" o Over 300 shareholders — mostly individual investors co Approximately 45,000 ADTV over past six months o Debt free and no preferred or convert
Slide 5: UHP Senior Leadership
UHP SENIOR LEADERSHIP Our senior team has extensive and relevant experience to accomplish our near-term objectives Brian Thom, + Over 20 years in financial advisory, overseeing capital raising for client Chief Executive Officer J.P.Morgan and guiding company sales efforts SOCIETE : ence i ic plannit
Slide 6: HemoStyp Technology Highlights
HEMOSTYP TECHNOLOGY HIGHLIGHTS" 1 Disruptive product in fast-growing hemostats market Unique properties of UHP's NORC may provide benefits in the high value human surgical setting Neutral pH causes no tissue damage and speeds the healing process Converts to a translucent gel allowing surgeon to visu
Slide 7: U.S. Surgical Hemostats Market Summary
U.S. SURGICAL HEMOSTATS MARKET SUMMARY FDA PMA approval would allow HemoStyp to pursue a $350+ million domestic market, with CE Mark and other markets to follow — Accessing the flowable (gel) market, while smaller, would boost the domestic market opportunity by 80% to $650 million U.S. Hemostat Mark
Slide 8: U.S. Hemostat Market Share Dynamics
U.S. HEMOSTAT MARKET SHARE DYNAMICS Approximate mechanical hemostat market shares Approximate flowable hemostat market shares = Surgicel family = Arista’ = Surgifoam — Other mechanical = Floseal = Surgiflo » Other flowable +1 Surgicel Original accounts for approximately 70% of hemostat 1 Baxter (Flo
Slide 9: HemoStyp Format Development Strategy
HEMOSTYP FORMAT DEVELOPMENT STRATEGY HemoStyp has the potential to build a portfolio of product formats to satisfy a broad range of surgical applications HemoStyp Gauze/Ciass It (Internal Use Loose weave NORC) jy PM Submission & Review/Surgica] Applications = = H H HemoStyp Gauze/Class Il (Topical H
Slide 10: FDA PMA Application Status
FDA PMA APPLICATION STATUS oO May 4, 2021: FDA notification that it has commenced Substantive Review process Q In late May, FDA provided list of specific areas where our PMA submission required clarification or supplemental information co Largely focused on product design and production process, and
Slide 11: Non-Class III Commercial Opportunities
NON-CLASS IIl COMMERCIAL OPPORTUNITIES Financial and human resources are now available to re-engage with 510k market opportunities in a more disciplined manner Hemodialysis Opportunity Emergency Medicine Opportunity Approximately 750,000 Americans have End Stage Renal Disease (ESRD) requiring dialys
Slide 12: Near Term Priorities to Grow Value
NEAR TERM PRIORITIES TO GROW VALUE We will maximize shareholder value through a sale of the Company as our technology’s value is proven The UHP team is focused on three areas of critical importance R&D milestones: Develop optimal gel formulation Develop and test powder format against ORC and Polysac
United Health Products — Investor Presentation (October 2021) on 6ix